20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T80543 | STE-MEK1(13) | ERK Activation Inhibitor Peptide,Ste-MPKKKPTPIQLNP-NH₂ | ERK |
STE-MEK1(13), a cell-permeable ERK1/2 inhibitor with IC50 values ranging from 13 to 30 μM, impedes the phosphorylation of ERK1/2, as demonstrated in studies [1] [2]. | |||
T63547 | MEK1/2-IN-2 | ||
MEK1/2-IN-2 is a potent, ATP-competitive MEK1/2 inhibitor that exhibits equal inhibitory effects on wild-type MEK1/2 and a group of MEK1/2 mutant cells. | |||
T79144 | PROTAC MEK1 Degrader-1 | PROTACs | |
PROTAC MEK1 Degrader-1, a targeted protein degradation agent, combines a MEK1 inhibitor with a von Hippel-Lindau ligand to effectively inhibit ERK1/2 phosphorylation. With a pIC50 value of 7.0, it exhibits antiproliferat... | |||
T76556 | MEK1 Derived Peptide Inhibitor 1 | ||
MEK1 Derived Peptide Inhibitor 1, a peptide inhibitor, prevents the in vitro activation of ERK2 by MEK1, exhibiting an inhibitory concentration (IC 50) of 30 μM. It is utilized in the study of cell-permeable [1]. | |||
T76557 | Myristoyl-MEK1 Derived Peptide Inhibitor 1 | ||
Myristoyl-MEK1 Derived Peptide Inhibitor 1, the myristoylated variant of MEK1 Derived Peptide Inhibitor 1, effectively inhibits ERK activation, demonstrating an inhibitory concentration (IC50) of 10 μM [1]. | |||
T72407 | C-Met/MEK1/Flt-3-IN-1 | ||
Antiproliferative Against-3 (comp 33) demonstrates significant activity against Hela (IC 50 = 0.21 µM), A549 (IC 50 = 0.39 µM), and MCF-7 (IC 50 = 0.33 µM) cell lines. Additionally, it induces apoptosis in a dose-depende... | |||
T6636 | Refametinib | BAY 86-97661,BAY 869766,RDEA119 | MEK |
Refametinib (RDEA119) (RDEA119, Bay 86-9766) is an effective, ATP non-competitive and specific inhibitor of MEK1/2 (IC50: 19/47 nM). | |||
T6692 | TAK-733 | TAK733,TAK 733 | MEK |
TAK-733 is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. | |||
T6131 | Pimasertib | AS703026,MSC1936369B,SAR 245509 | MEK |
Pimasertib (AS703026) is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. | |||
T6218 | Selumetinib | ARRY-142886,AZD6244 | Apoptosis , ERK , MEK |
Selumetinib (AZD6244) (AZD6244) is an effective, specific inhibitor of MEK1 and ERK1/2 phosphorylation (IC50: 14/10 nM). | |||
T5412 | RO4987655 | CH4987655,RG7167 | MEK |
RO4987655 (RG7167) is an orally active and highly selective MEK inhibitor (IC50: 5.2 nM for MEK1/MEK2). | |||
T6843 | GDC-0623 | G-868,GDC0623,RG 7421,MEK inhibitor 1 | Apoptosis , MEK |
GDC-0623 (RG 7421) is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1. | |||
T2708 | SL327 | SL 327,SL-327 | MEK , DNA/RNA Synthesis |
SL327 is a selective inhibitor for MEK1/2 with IC50 of 0.18 μM/0.22 μM; able to transport through the blood-brain barrier. | |||
T5857 | Trametinib (DMSO solvate) | Trametinib DMSO solvate,GSK-1120212 (DMSO solvate),Trametinib dimethyl sulfoxide,JTP-74057 (DMSO solvate) | Apoptosis , MEK |
Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate)) is a Highly Potent and Selective MEK Inhibitor that specifically inhibits MEK1/2(IC50 :2 nM) | |||
T2125 | Trametinib | GSK1120212,JTP-74057 | Apoptosis , MEK , Autophagy |
Trametinib (GSK1120212) is a MEK inhibitor that inhibits MEK1 and MEK2 (IC50=0.7/0.9 nM) with ATP non-competitive and oral activity. Trametinib activates autophagy and induces apoptosis. | |||
T2443 | CI-1040 | PD 184352 | Apoptosis , MEK |
CI-1040 (PD 184352) (PD184352) is an ATP non-competitive MEK1/2 inhibitor (IC50: 17 nM). | |||
T6223 | U0126-EtOH | U0126 Ethanol,U0126 | Mitophagy , Influenza Virus , MEK , Autophagy |
U0126-EtOH (U0126 Ethanol) is a non-ATP competitive specific inhibitor of MEK1/2 (IC50: 0.07/0.06 μM). | |||
T2623 | PD98059 | PD 98059 | ERK , Aryl Hydrocarbon Receptor , MEK , Autophagy |
PD98059 is an MEK inhibitor that inhibits MEK1 and MEK2 (IC50=2/50 μM) and is non-ATP-competitive. PD98059 is also antagonistic as a ligand for AHR. PD98059 inhibits autophagy. | |||
T6152 | PD318088 | MEK | |
PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor, binding simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site. | |||
T2508 | Binimetinib | ARRY-438162,ARRY-162,MEK162 | MEK , Autophagy |
Binimetinib (ARRY-162) (MEK162, ARRY-162, ARRY-438162) is an orally available inhibitor of MEK1/2 (IC50: 12 nM) in a cell-free assay. |